GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement

GT Biopharma, Inc.

All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.
Additional holder provided waiver on September 25, 2025, completing the agreement across all holders.
Waiver eliminates potential redemption trigger that could require cash outlay, improving liquidity.
No financial impact disclosed; modification alters preferred stockholder rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.